F. Hoffmann-La Roche had ten patents in advanced materials during Q4 2023. The patents filed by F. Hoffmann-La Roche Ltd in Q4 2023 focus on high throughput methods for optimizing and manufacturing lipid nanoparticle compositions, as well as improved magnetic glass particles for nucleic acid capture and analysis. These innovations enable efficient optimization of manufacturing conditions for LNP-based therapeutics and provide advancements in nucleic acid enrichment and purification techniques. GlobalData’s report on F. Hoffmann-La Roche gives a 360-degreee view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights F. Hoffmann-La Roche Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

F. Hoffmann-La Roche grant share with advanced materials as a theme is 30% in Q4 2023. Grant share is based on the ratio of number of grants to total number of patents.

Recent Patents

Application: High-throughput methods for preparing lipid nanoparticles and uses thereof (Patent ID: US20230330023A1)

The patent filed by F. Hoffmann-La Roche Ltd. describes high-throughput methods for optimizing and manufacturing lipid nanoparticle (LNP) compositions efficiently. The disclosed method involves obtaining intermixable solutions with a payload and self-assembling molecules, varying conditions such as injection sequence, speed, volume, and mixing duration, and measuring parameters like encapsulation efficiency and particle size distribution to determine optimal manufacturing parameters for LNP-based therapeutics. The process enables the production of LNPs with high encapsulation efficiency, specific particle sizes, and formulation stability, crucial for effective drug delivery systems.

The claims detail a method for manufacturing LNPs with various payloads, including oligonucleotides, mRNA, polypeptides, and small molecules, by systematically varying parameters like lipid concentration, composition ratio, and PEGylation percentage. The optimized LNPs exhibit characteristics such as high encapsulation efficiency, specific size distribution, and stability over time. The patent also outlines a workflow for high-throughput screening of LNP formation parameters using a robotic liquid handler and measurement instruments, allowing for efficient optimization and production of LNPs with desired characteristics for effective drug delivery applications.

To know more about GlobalData’s detailed insights on F. Hoffmann-La Roche, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.